In this real‐life observational multicenter Italian study, we evaluated the efficacy and safety of momelotinib in patients with primary or secondary MF and anemia, and we confirm its role as a disease‐modifying agent with a unique dual mechanism: JAK1/2 inhibition and suppression of hepcidin via ACVR1 blockade. Here, JAK1 is linked to anemia.